Skip to main content
Sarcoma logoLink to Sarcoma
. 2003 Sep-Dec;7(3-4):153–157. doi: 10.1080/13577140310001644779

Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity

René L van der Hul 1, Caroline Seynaeve 2, Bert N van Geel 1, Jaap Verweij 2,
PMCID: PMC2395524  PMID: 18521380

Abstract

Purpose: To evaluate the tolerance of a low dose chemotherapy regimen for desmoid tumours.

Patients and methods: Patients with desmoids for whom radical resection was impossible or related to extensive mutilation were treated with chemotherapy. Treatment consisted of intravenous methotrexate at a dose of 50mg and vinblastine at a dose of 10mg weekly, scheduled to be given for a total period of 1 year. Doses were reduced and/or delayed on an individual basis, depending on the observed type of toxicity.

Results: Ten patients (six males; four females), median age 43 years (range17–75), median WHO performance score 1 (range 0–1), were treated. None of them was able to complete the treatment as scheduled, due to observed side effects, while in two patients treatment was also discontinued because of progressive disease. In six patients, less than 50% of the projected administrations and dose could be given. Severe organ toxicity was noted in three patients (one interstitial pneumonitis, two toxic hepatitis), which, however, was reversible in all cases.

Discussion: Methotrexate and vinblastine given at this dose and schedule lead to an unacceptable level of toxicity for a long-term treatment, and cannot be recommended for standard use.

Full Text

The Full Text of this article is available as a PDF (57.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azzarelli A., Gronchi A., Bertulli R., Tesoro J. D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Ferrari A., Pilotti S. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001 Sep 1;92(5):1259–1264. doi: 10.1002/1097-0142(20010901)92:5<1259::aid-cncr1446>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  2. Nuyttens J. J., Rust P. F., Thomas C. R., Jr, Turrisi A. T., 3rd Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer. 2000 Apr 1;88(7):1517–1523. [PubMed] [Google Scholar]
  3. Quinn S. F., Erickson S. J., Dee P. M., Walling A., Hackbarth D. A., Knudson G. J., Moseley H. S. MR imaging in fibromatosis: results in 26 patients with pathologic correlation. AJR Am J Roentgenol. 1991 Mar;156(3):539–542. doi: 10.2214/ajr.156.3.1899752. [DOI] [PubMed] [Google Scholar]
  4. Shields C. J., Winter D. C., Kirwan W. O., Redmond H. P. Desmoid tumours. Eur J Surg Oncol. 2001 Dec;27(8):701–706. doi: 10.1053/ejso.2001.1169. [DOI] [PubMed] [Google Scholar]
  5. Weiss A. J., Horowitz S., Lackman R. D., Lackmen R. D. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol. 1999 Apr;22(2):193–195. doi: 10.1097/00000421-199904000-00020. [DOI] [PubMed] [Google Scholar]
  6. Weiss A. J., Lackman R. D. Low-dose chemotherapy of desmoid tumors. Cancer. 1989 Sep 15;64(6):1192–1194. doi: 10.1002/1097-0142(19890915)64:6<1192::aid-cncr2820640605>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  7. Zisman D. A., McCune W. J., Tino G., Lynch J. P., 3rd Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2001 Oct;18(3):243–252. [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES